Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …

Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor
genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and …

PARP inhibitors are approved for treating advanced prostate cancers (APC) with various
defective DNA repair genes; however, further studies to clinically qualify predictive …

Prostate cancer (PCa) incidence and mortality have rapidly increased in China. Notably,
unique epidemiological characteristics of PCa are found in the Chinese PCa population …

The treatment landscape of metastatic prostate cancer has evolved significantly over the
past two decades. Several landmark phase 3 trials led to new drug approvals and rapid …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but various areas of management still lack high …

Background Poly (ADP-ribose) polymerase (PARP) inhibitors have antitumour activity
against metastatic castration-resistant prostate cancers with DNA damage response (DDR) …

Simple Summary Cells respond to genotoxic stress through complex protein pathways
called DNA damage response (DDR). These mechanisms ensure the preservation of …

Radiotherapy and chemical DNA-damaging agents are among the most widely used
classes of cancer therapeutics today. Double-strand breaks (DSB) induced by many of these …